Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
10.54
-0.93 (-8.11%)
At close: Sep 29, 2026, 4:00 PM EDT
10.59
+0.05 (0.47%)
After-hours: Sep 29, 2026, 7:54 PM EDT
Immix Biopharma Employees
As of December 31, 2025, Immix Biopharma had 21 total employees, including 18 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
21
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,900,820
Market Cap
754.02M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | 0 | - | 21 | 0 |
| Dec 31, 2024 | 21 | 4 | 23.53% | 18 | 3 |
| Dec 31, 2023 | 17 | 6 | 54.55% | 14 | 3 |
| Dec 31, 2022 | 11 | 9 | 450.00% | 9 | 2 |
| Dec 31, 2021 | 2 | - | - | 2 | 0 |
| Sep 30, 2021 | 2 | - | - | 2 | 0 |
| Jun 30, 2021 | 2 | - | - | 2 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| Wave Life Sciences | 317 |
| Olema Pharmaceuticals | 150 |
| Solid Biosciences | 121 |
| Verastem | 102 |
| Annexon | 92 |
| Inventiva | 77 |
| Aclaris Therapeutics | 73 |
IMMX News
- 15 hours ago - Immix Biopharma price target raised to $30 from $27 at BofA - TheFly
- 18 hours ago - Immix Biopharma Transcript: Study result - Transcripts
- 18 hours ago - Immix Biopharma Press release: Study result - Filings
- 19 hours ago - Immix announces 89% CR rate in interim update across NEXICART-2 patients - TheFly
- 19 hours ago - Immix Biopharma prices 11.36M share registered offering at $11.00 - TheFly
- 19 hours ago - Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock - GlobeNewsWire
- 19 hours ago - Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis - GlobeNewsWire
- 14 days ago - Immix Biopharma price target raised to $26 from $15 at Mizuho - TheFly